Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions β€” written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Bitolterol

Introduction

Overview

Overview

Bitolterol mesylate (Tornalate) is a Ξ²2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma[1][2] and COPD.[3][4][5] In these disorders there is a narrowing of the airways (bronchi and their ramifications) that carry air to the lungs. Muscle spasm and inflammation within the bronchi get worse this narrowing. Bitolterol relaxes the smooth muscles present continuously around the bronchi and bronchioles facilitating the flow of air through them.

Bitolterol has a rapid onset of action (2–5 minutes) and may last up to 6–8 hours.[6] The drug, alone or in co-administration with theophylline, doesn’t show cardiotoxic effect.[7]

The USA Food and Drug Administration (FDA) approved bitolterol in December 1984. The drug was withdrawn from the market by Γ‰lan Pharmaceuticals in 2001.

References

References

  1. ↑ Nathan RA, Bodman SF, Storms WW, Mingo TS (June 1986). “Bitolterol mesylate aerosol in adults with steroid-dependent asthma: a comparison with isoproterenol hydrochloride aerosol”. Ann Allergy. 56 (6): 494–9. PMIDΒ 3717716.
  2. ↑ Nathan RA, Bernstein IL, Bronsky EA, Bush RK, Chervinsky P, Condemi JJ, Dockhorn RJ, Pinnas JL, Repsher LH (May 1987). “Comparison of the bronchodilator effects of nebulized bitolterol mesylate and isoproterenol hydrochloride in steroid-dependent asthma”. J. Allergy Clin. Immunol. 79 (5): 822–9. doi:10.1016/0091-6749(87)90216-8. PMIDΒ 3571773.
  3. ↑ Friedel HA; Brogden RN (1988). “Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease”. Drugs. 35: 22–41. doi:10.2165/00003495-198835010-00002.
  4. ↑ Anderson, JR.; Groves, PM.; Schwartz, GE. (Jan 1979). “Early Career Awards for 1978 (John Robert Anderson, Philip M. Groves, Gary E. Schwartz)”. Am Psychol. 34 (1): 69–79. PMIDΒ 396832.
  5. ↑ Petty, TL.; Scoggin, CH.; Rollins, DR.; Repsher, LH. (Sep 1984). “Bitolterol compared to isoproterenol in advanced chronic obstructive pulmonary disease”. Chest. 86 (3): 404–8. doi:10.1378/chest.86.3.404. PMIDΒ 6380974.
  6. ↑ Kass, I.; Mingo, TS. (Aug 1980). “Bitolterol mesylate (WIN 32784) aerosol. A new long-acting bronchodilator with reduced chronotropic effects”. Chest. 78 (2): 283–7. doi:10.1378/chest.78.2.283. PMIDΒ 6995040.
  7. ↑ Kemp, JP.; Chervinsky, P.; Orgel, HA.; Meltzer, EO.; Noyes, JH.; Mingo, TS. (Jan 1984). “Concomitant bitolterol mesylate aerosol and theophylline for asthma therapy, with 24 hr electrocardiographic monitoring”. J Allergy Clin Immunol. 73 (1 Pt 1): 32–43. doi:10.1016/0091-6749(84)90481-0. PMIDΒ 6693665.

Template:Asthma and copd rx

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]